Effect of Avastin in Juxtafoveal Telangiectasias

Asociación para Evitar la Ceguera en México

Overview

Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias

After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Telangiectasis

Interventions

BevacizumabDRUG

Intravitreal injection of BevacizumabPROCEDURE

Eligibility

Sex: ALLMin age: 40 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion * Patients with Idiopathic Juxtafoveal Retinal Telangiectasias Exclusion Criteria: * Diabetic Retinopathy and Diabetic Macular Edema * Hypertensive Retinopathy * Choroidal Neovascularization

Locations (1)

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

Best corrected Visual Acuity

Fluorescein Angiogram: Leakage

Optical Coherence Tomography: Retinal thickness

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.